Otonomy to Present at the Bank of America Merrill Lynch Health Care Conference
May 10 2017 - 04:05PM
Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company
focused on the development and commercialization of innovative
therapeutics for diseases and disorders of the ear, today announced
that David A. Weber, Ph.D., president and chief executive officer,
will present at the Bank of America Merrill Lynch 2017 Health Care
Conference on Wednesday, May 17, 2017 at 5:00 p.m. PDT (8:00 p.m.
EDT) at the Encore at the Wynn Hotel in Las Vegas.
A live audio webcast of the presentation will be available
through the Events and Presentations page of the company's website
(www.otonomy.com).
About Otonomy
Otonomy is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics for
diseases and disorders of the ear. OTIPRIO® (ciprofloxacin otic
suspension) is approved in the United States for use during
tympanostomy tube placement surgery in pediatric patients, an sNDA
has been submitted to the FDA for acute otitis externa (AOE) and a
successful Phase 2 trial has been completed in patients with acute
otitis media with tympanostomy tubes (AOMT). OTIVIDEX™ (formerly
OTO-104) is a steroid in development for the treatment of Ménière's
disease and other balance and hearing disorders. Two Phase 3 trials
in Ménière's disease patients are ongoing, AVERTS-1 in the United
States and AVERTS-2 in Europe, with AVERTS-1 results expected in
the third quarter of 2017 and AVERTS-2 results expected by the end
of 2017. In addition, a Phase 2 trial of OTIVIDEX is underway in
patients at risk for cisplatin-induced hearing loss. OTO-311 is an
NMDA receptor antagonist for the treatment of tinnitus that has
completed a Phase 1 clinical safety trial with a Phase 2 trial
expected to be initiated in the second half of 2017. A fourth
program targeting sensorineural hearing loss including age-related
hearing loss is in preclinical development. Otonomy’s proprietary
formulation technology utilizes a thermosensitive gel and drug
microparticles to enable single dose treatment by a physician. For
additional information please visit www.otonomy.com.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or the future financial or operating performance of Otonomy.
Forward-looking statements in this press release include, but are
not limited to, the timing of Phase 3 results for OTIVIDEX and the
timing of a Phase 2 clinical trial for OTO-311. Otonomy's
expectations regarding these matters may not materialize, and
actual results in future periods are subject to risks and
uncertainties. Actual results may differ materially from those
indicated by these forward-looking statements as a result of these
risks and uncertainties, including but not limited to: Otonomy's
limited operating history and its expectation that it will incur
significant losses for the foreseeable future; Otonomy's ability to
obtain additional financing; Otonomy's dependence on the commercial
success of OTIPRIO and the regulatory success and advancement of
additional product candidates, such as OTIVIDEX and OTO-311, and
label expansion indications for OTIPRIO; the uncertainties inherent
in the clinical drug development process, including, without
limitation, Otonomy's ability to adequately demonstrate the safety
and efficacy of its product candidates, the nonclinical and
clinical results for its product candidates, which may not support
further development, and challenges related to patient enrollment
in clinical trials; Otonomy's ability to obtain regulatory approval
for its product candidates; side effects or adverse events
associated with Otonomy's product candidates; competition in the
biopharmaceutical industry; Otonomy's dependence on third parties
to conduct nonclinical studies and clinical trials; the timing and
outcome of hospital pharmacy and therapeutics reviews and other
facility reviews; the impact of coverage and reimbursement
decisions by third-party payors on the pricing and market
acceptance of OTIPRIO; Otonomy's dependence on third parties for
the manufacture of OTIPRIO and product candidates; Otonomy's
dependence on a small number of suppliers for raw materials;
Otonomy's ability to protect its intellectual property related to
OTIPRIO and its product candidates in the United States and
throughout the world; expectations regarding potential market size,
opportunity and growth; Otonomy's ability to manage operating
expenses; implementation of Otonomy's business model and strategic
plans for its business, products and technology; and other risks.
Information regarding the foregoing and additional risks may be
found in the section entitled "Risk Factors" in Otonomy's Annual
Report on Form 10-Q filed with the Securities and Exchange
Commission (the "SEC") on May 4, 2017, and Otonomy's future reports
to be filed with the SEC. The forward-looking statements in this
press release are based on information available to Otonomy as of
the date hereof. Otonomy disclaims any obligation to update any
forward-looking statements, except as required by law.
Contacts:
Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
619.849.5377
heidi@canalecomm.com
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Mar 2023 to Mar 2024